Browsing Tag
JR-141
1 post
JCR Pharmaceuticals completes global Phase III enrollment for JR-141 targeting Hunter syndrome’s neurological symptoms
JCR Pharmaceuticals completes global Phase III enrollment for JR-141, targeting Hunter syndrome CNS symptoms with its BBB-penetrating enzyme therapy.
July 3, 2025